β3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin

Molecular Cancer Research

Volumn 1, Issue 11, 2003, Pages 810-819

  Furger, Kara A ^a   Allan, Alison L ^a   Wilson, Sylvia M ^a   Hota, Charulata ^a   Vantyghem, Sharon A ^a   Postenka, Carl O ^a   Al Katib, Waleed ^a   Chambers, Ann F ^a   Tuck, Alan B ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; INTEGRIN; OSTEOPONTIN; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CARCINOGENESIS; CARCINOMA CELL; CELL ADHESION; CELL DIVISION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LATENT PERIOD; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; VECTOR CONTROL;

ANIMALS; BLOTTING, NORTHERN; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN BETA3; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OSTEOPONTIN; SIALOGLYCOPROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0141542626     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., Dvorak, H. F., and Senger, D. R. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145: 610-623, 1994.
2. Furger, K. A., Menon, R. K., Tuck, A. B., Bramwell, V. H., and Chambers, A. F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med., 1: 621-632, 2001.
3. Singhal, H., Bautista, D. S., Tonkin, K. S., O'Malley, F. P., Tuck, A. B., Chambers, A. F., and Harris, J. F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3: 605-611, 1997.
4. Tuck, A. B., O'Malley, F. P., Singhal, H., Tonkin, K. S., Harris, J. F., Bautista, D., and Chambers, A. F. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med., 121: 578-584, 1997.
5. Tuck, A. B., O'Malley, F. P., Singhal, H., Harris, J. F., Tonkin, K. S., Kerkvliet, N., Saad, Z., Doig, G. S., and Chambers, A. F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer, 79: 502-508, 1998.
6. Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., and Fisher, L. W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 7: 4060-4066, 2001.
7. Rudland, P. S., Platt-Higgins, A., El-Tanani, M., De Silva Rudland, S., Barraclough, R., Winstanley, J. H., Howitt, R., and West, C. R. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res., 62: 3417-3427, 2002.
8. Chambers, A. F., Wilson, S. M., Kerkvliet, N., O'Malley, F. P., Harris, J. F., and Casson, A. G. Osteopontin expression in lung cancer. Lung Cancer, 15: 311-323, 1996.
9. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K., Schorge, J. O., Feltmate, C. M., Berkowtiz, R. S., Cramer, D. W., and Mok, S. C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 278: 1671-1679, 2002.
10. Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., Cantor, A., and Coppola, D. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst., 94: 513-521, 2002.
11. Hotte, S. J., Winquist, E. W., Stitt, L., Wilson, S. M., and Chambers, A. F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer, 95: 506-512, 2002.
12. Ye, Q. H., Qin, L. X., Forgues, M., He, P., Kim, J. W., Peng, A. C., Simon, R., Li, Y., Robles, A. I., Chen, Y., Ma, Z. C., Wu, Z. Q., Ye, S. L., Liu, Y. K., Tang, Z. Y., and Wang, X. W. Predicting hepatitis B virus-positive metastatic hepatocellular using gene expression profiling and supervised machine learning. Nat. Med., 9: 416-423, 2003.
13. Oates, A. J., Barraclough, R., and Rudland, P. S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumor model. Oncogene, 13: 97-104, 1996.
14. Sung, V., Gilles, C., Murray, A., Clarke, R., Aaron, A. D., Azumi, N., and Thompson, E. W. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp. Cell Res., 241: 273-284, 1998.
15. Tuck, A. B., Arsenault, D. M., O'Malley, F. P., Hota, C., Ling, M. C., Wilson, S. M., and Chambers, A. F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18: 4237-4246, 1999.
16. Urquidi, V., Sloan, D., Kawai, K., Agarwal, D., Woodman, A. C., Tarin, D., and Goodison, S. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin. Cancer Res., 8: 61-74, 2002.
17. Xuan, J. W., Hota, C., and Chambers, A. F. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J. Cell. Biochem., 54: 247-255, 1994.
18. Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., and Chambers, A. F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem., 78: 465-475, 2000.
19. Tuck, A. B., Hota, C., Wilson, S. M., and Chambers, A. F. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22: 1198-1205, 2003.
20. Tuck, A. B., Hota, C., and Chambers, A. F. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res. Treat., 70: 197-204, 2001.
21. Sodek, J., Ganss, B., and McKee, M. D. Osteopontin. Crit. Rev. Oral Biol. Med., 11: 279-303, 2000.
22. Weber, G. F., Ashkar, S., Glimcher, M. J., and Cantor, H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271: 509-512, 1996.
23. 1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res., 59: 219-226, 1999.
24. van Dijk, S., D'Errico, J. A., Somerman, M. J., Farach-Carson, M. C., and Butler, W. T. Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment. J. Bone Miner. Res., 8: 1499-1506, 1993.
25. v integrins. J. Cell. Biochem., 62: 123-131, 1996.
26. 5. J. Biol. Chem., 270: 26232-26238, 1995.
27. 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology, 136: 2984-2992, 1995.
28. v integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. & Exp. Metastasis, 16: 50-61, 1998.
29. Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, V., Cohen, C., Connolly, J., and Sager, R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res., 50: 7351-7357, 1990.
30. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res., 50: 717-721, 1990.
31. Tuck, A. B. and Chambers, A. F. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia, 6: 419-429, 2001.
32. Markert, J. M., Fuller, C. M., Gillespie, G. Y., Bubien, J. K., McLean, L. A., Hong, R. L., Lee, K., Gullans, S. R., Mapstone, T. B., and Benos, D. J. Differential gene expression profiling in human brain tumors. Physiol. Genomics, 5: 21-33, 2001.
33. Euer, N., Schwirzke, M., Evtimova, V., Burtscher, H., Jarsch, M., Tarin, D., and Weidle, U. H. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res., 22: 733-740, 2002.
34. Denhardt, D. T. and Chambers, A. F. Overcoming obstacles to metastasis- defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J. Cell. Biochem., 56: 48-51, 1994.
35. Feng, B., Rollo, E. E., and Denhardt, D. T. OPN may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by targeted ribozyme. Clin. & Exp. Metastasis, 13: 453-462, 1995.
36. 3 integrin-induced endothelial cell survival. J. Cell Biol., 141: 1083-1093, 1998.
37. Geissinger, E., Weisser, C., Fischer, P., Schartl, M., and Wellbrock, C. Autocrine stimulation by osteopontin contributes to antiapoptotic signaling of melanocytes in dermal collagen. Cancer Res., 62: 4820-4828, 2002.
38. Eliceiri, B. P. Integrin and growth factor receptor crosstalk. Circ. Res., 89: 1104-1010, 2001.
39. Weber, G. F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta. 1552: 61-85, 2001.
40. Nesbit, M. and Herlyn, M. Adhesion receptors in human melanoma progression. Invasion Metastasis, 14: 131-146, 1994.
41. Gui, G. P., Wells, C. A., Browne, P. D., Yeomans, P., Jordan, S., Puddefoot, J. R., Vinson, G. P., and Carpenter, R. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery, 117: 102-108, 1995.
42. 3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol., 5: 127-135, 1996.
43. 3 integrin in melanomas and nevi. Hum. Pathol., 30: 562-567, 1999.
44. Felding-Habermann, B., O'Toole, T. E., Smith, J. W., Fransvea, E., Ruggeri, Z. M., Ginsberg, M. H., Hughes, P. E., Pampori, N., Shattil, S. J., Saven, A., and Mueller, B. M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA, 98: 1853-1858, 2001.
45. 3 in prostate cancer progression. Neoplasia, 4: 191-194, 2002.
46. Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., Kohri, K., Nomura, S., and Kitamura, Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers: possible involvement of osteopontin in development of calcifying foci. Lab. Invest., 72: 64-69, 1995.